Anti-EGFR Antibody-Drug Conjugate Carrying an Inhibitor Targeting CDK Restricts Triple-Negative Breast Cancer Growth.

Anthony Cheung Alicia M Chenoweth Annelie Johansson Roman Laddach Naomi Jayne Guppy Jennifer Trendell Benjamina Esapa Antranik Mavousian Blanca Navarro-Llinas Syed Haider Pablo Romero-Clavijo Ricarda M Hoffmann Paolo Andriollo Khondaker Miraz Rahman Paul Jackson Sophia Tsoka Sheeba Irshad Ioannis Roxanis Anita Grigoriadis David E Thurston Christopher J Lord Andrew N J Tutt Sophia N Karagiannis

Published in: Clinical cancer research : an official journal of the American Association for Cancer Research (2024)

Exploiting EGFR overexpression, and dysregulated cell cycle in aggressive and treatment-refractory tumors, a cetuximab-CDK inhibitor ADC may provide selective and efficacious delivery of cell cycle-targeted agents to basal-like/TNBCs, including chemotherapy-resistant residual disease.

Keyphrases

cell cycle
cell proliferation
small cell lung cancer
cancer therapy
epidermal growth factor receptor
tyrosine kinase
locally advanced
drug delivery
transcription factor
magnetic resonance
rectal cancer
wild type